Subscribe to Search results

An editorial in the "British Medical Journal" asserted that the protein fractionation centres lacked sufficient staff, accommodation, equipment and the basic organisational units to do the job.

Published on:

In a letter from Dr Biggs to Dr Godber, she called attention to the lack of organisation, apparatus and buildings needed in order to produce Factor 8.

Published on:

In the minutes of an AIDS group of haemophilia centre directors' meeting, Dr Mortimer told the meeting that he was concerned to see that a large number of centres were still using non-heat-treated Factor 8, and suggested that all directors should be advised not to use it.

Published on:

During a meeting of the AIDS group of haemophilia centre directors, directors were recommended to use only heat-treated products now these were available.

Published on:

At a UKHCDO Hepatitis Working Party meeting Dr Craske identified eight patients treated with (unheated) Factor 9 who had seroconverted.

Published on:

Haemofact No 6 reported that Lord Glenarthur, Parliamentary Under-Secretary of State for Health, speaking in the House of Lords, had made it clear that all home produced Factor 8 would be heat treated from April 1985.

Published on:

The "Daily Mail" published a front page article with the headline "AIDS Virus kills man in Britain".

Published on:

The "Daily Express" published an article titled "Twin bid to curb killer AIDS peril".

Published on:

"The Times" published an article titled "Treated blood cuts Aids risk to haemophiliacs".

Published on:

Douglas Starr, in his book "An Epic History of Medicine and Commerce" commented: "Once AIDS became an acknowledged reality, the drug firms quickly developed screening tests and virus-killing technologies...If they had heeded the warnings of Factor VIII...they would have abandoned the high-risk collection centres sooner and worked more intensively on virus-killing technology."

Published on:

Professor Titmuss published his book "The Gift Relationship".

Published on:

The use of genetically engineered blood clotting agents was announced in October 1988 at the Royal Free Hospital.

Published on:

At a Haemophilia Society Executive Committee meeting it was reported that "the introduction of heat-treated materials has been 'patchy' and that at least one Supra-Region had not yet introduced heat-treated materials."

Published on:

Dr Denis Donohue of the FDA asked the pharmaceutical companies to stop using blood collected from donors likely to have high levels of antibodies to hepatitis.

Published on:

By this time, self-sufficiency had largely been achieved.

Published on:

Professor Edward Tuddenham told the Inquiry that inactivation could and should have been achieved earlier.

Published on:

Christopher Bishop asserted in his oral evidence that Armour had done: "everything possible to provide the best possible treatment and the most up-to-date systems in accordance with the state of art at that time."

Published on:

Dr Peter Foster stated in his oral evidence to the Inquiry that it was difficult dealing with a possible virus, the structure of which was unknown. However, both BPL and PFC managed to inactivate NANBH before the structure of Hepatitis C was known.

Published on:

Experiments were conducted by Dr Shohachi Wada on behalf of Cutter to see if the hepatitis virus with which Factor 9 was spiked could be inactivated whilst the Fator 9 was kept active.

Published on:

Leveton and others published "HIV and the Blood Supply: An Analysis of Crisis Decisionmaking".

Published on: